Cellular Biomedicine Group, a China-based regenerative medicine company, will conduct a reverse merger with EastBridge Investment Group of the US; Guangzhou BeBetter Medicine signed a collaborative research agreement with Taiwan's PharmaEngine to develop oncology drugs; Tianjin KingYork Group and Innovata of Hong Kong formed an inhaled drug JV that will target asthma; and Sichuan Kelun Pharma paid $135 million to purchase a 12.3% stake in Lijun International Pharma. More details…. Stock Symbols: (OTCQB: EBIG) (TWO: 4162) (SHE: 002422) (HK: 2005) Share this with colleagues: // //